Amneal Pharmaceuticals, Inc. (AMRX) Stock Price, Financials & Summary

Price chart

Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19

Key dataOct 19, 2026

Open$19.10

From 52W high−5.56%

Volume2.10M

Market cap$6.18B

P/E (TTM)38.9x

P/S (TTM)2.0x

Div yield—

Key dataOct 19, 2026

Open

$19.10

From 52W high

−5.56%

Volume

2.10M

Market cap

$6.18B

ValuationView details →

P/E (Fwd)

17.8x

EV/EBITDA

13.7x

P/E (TTM)

38.9x

RSI (14)

50.0

MomentumView details →

1D Return

+0.94%

YTD Return

+52.90%

SummaryUpdated Jun 1, 2026

Amneal Pharmaceuticals, Inc. (NYSE:AMRX) is a specialty and generic pharmaceutical company founded in 2002 and headquartered in Bridgewater, New Jersey. The company went public in May 2018 following its transformation from Atlas Holdings, Inc. Amneal has evolved from a traditional generic drug manufacturer into a diversified pharmaceutical company with operations spanning generic medicines, specialty branded products, and healthcare distribution services. The company operates manufacturing facilities in the United States, India, and Ireland, serving customers globally through a comprehensive portfolio of pharmaceutical products and services.

Ask drillr about Amneal Pharmaceuticals, Inc. →

ValuationView details →

P/E (Fwd)

17.8x

P/E (TTM)

38.9x

EV/EBITDA

13.7x

EV/Sales

2.9x

P/S (TTM)

2.0x

P/B (TTM)

187.2x

ProfitabilityView details →

Gross Margin

39.32%

Net Margin

5.05%

EBITDA Margin

20.92%

ROE (TTM)

476.51%

ROA (TTM)

4.17%

Asset Turnover

0.85x

GrowthView details →

Revenue YoY

+9.28%

EPS YoY

+4825.74%

FCF YoY

−68.34%

Revenue CAGR 3Y

+10.92%

EPS CAGR 3Y

+160.53%

EBITDA YoY

+11.70%

MomentumView details →

1D Return

+0.94%

YTD Return

+52.90%

1Y Return

+88.14%

RSI (14)

50.0

vs 50D SMA

+3.66%

vs 200D SMA

+25.18%

Capital & dividendView details →

Debt/Equity

84.54x

Current Ratio

2.20x

Quick Ratio

1.44x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

$0.30

EPS Surprise

34.83%

Beats (12Q)

11/12

Next Q EPS Est

$0.22

Avg Surprise (4Q)

41.34%

Rev Surprise

3.64%

Financials snapshotView financials →

Revenue (TTM)

3.12B

Net Income (TTM)

157.36M

Op. CF (TTM)

200.78M

Next earningsNov 3, 2026 →

Latest newsMore news →

Amneal Pharmaceuticals announced that it will report its third-quarter 2026 financial results before market open on November 3, 2026, and host an audio webcast at 8:30 a.m. ET.12d ago

The FDA approved Amneal Pharmaceuticals' Lanreotide Injection, a long-acting oncology treatment, and Amneal immediately launched the product commercially.31d ago

Similar companies

辰欣药业603367.SH China Traditional Chinese Medicine Holdings Co. Limited00570.HK 昆药集团600422.SH Lantheus Holdings, Inc.LNTH 亚虹医药-U688176.SH Shenzhen Hepalink Pharmaceutical Group Co., Ltd.09989.HK Find similar companies →

Latest newsMore news →

Amneal Pharmaceuticals announced that it will report its third-quarter 2026 financial results before market open on November 3, 2026, and host an audio webcast at 8:30 a.m. ET.12d ago The FDA approved Amneal Pharmaceuticals' Lanreotide Injection, a long-acting oncology treatment, and Amneal immediately launched the product commercially.31d ago